Description: BioPorto A/S, an in-vitro diagnostics company, provides biomarker tools and antibodies for clinical research in Europe, North America, Asia, and internationally. It offers the neutrophil gelatinase-associated lipocalin test, a quantitative particle-enhanced turbidimetric immunoassay designed to run on automated clinical chemistry analyzers; monoclonal antibodies for scientific, pharmaceutical, and clinical research; and enzyme-linked immunosorbent assay kits, as well as generic rapid assay device for custom lateral flow assays. BioPorto A/S was incorporated in 1917 and is based in Hellerup, Denmark.
Home Page: bioporto.com
Tuborg Havnevej 15, st.
Hellerup,
2900
Denmark
Phone:
45 45 29 00 00
Officers
| Name | Title |
|---|---|
| Mr. Peter Moerch Eriksen B.B.A., BBA | Chief Executive Officer |
| Mr. Niels Hoey Nielsen | Executive VP & CFO |
| Dr. Lars Otto Uttenthal | Chief Scientific Officer |
| Ms. Gry Husby Larsen | Executive VP & Chief Legal Officer |
| Ms. Jennifer Zonderman | SVP of Global Marketing & US Commercialization |
| Mr. Nis Kruse | Executive VP of Strategic Partnerships and GM of EMEA & APAC |
| Mr. Jeffrey N. Haas | President & CEO of BioPorto Inc. |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 8.3866 |
| Price-to-Sales TTM: | 3.2025 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 27 |